Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2025-12-24 @ 11:40 PM
NCT ID:
NCT00088751
Eligibility Criteria:
* INCLUSION CRITERIA:
1. FTD as diagnosed by the Lund-Manchester criteria including patients with diagnoses of Semantic Dementia or Primary Progressive Aphasia.
2. Ages 45 to 95 years old.
3. Mild-to-moderate (CDR 1 to 2) FTD with an assigned durable power of attorney.
EXCLUSION CRITERIA:
1. Diagnosis of any form of dementia besides FTD, including AD, Lewy body dementia, vascular dementia, dementia associated with Parkinson's disease, Corticobasal Degeneration and Progressive Supranuclear Palsy.
2. Severe dementia (CDR 3).
3. Known allergy or serious adverse reaction to quetiapine or dextroamphetamine.
4. Patient is already receiving a stimulant (methylphenidate, dextroamphetamine, pemoline, or modafinil), or an antipsychotic medication, typical or atypical, including prochlorperazine and metoclopromide.
5. Patients taking any of the following medications because of their potential interaction with dextroamphetamine: MAO use currently or within 14 days prior to start of study, Furazolidone, Guanethidine, norepinephrine, sibutramine, tricyclic antidepressants, carbonic anhydrase inhibitors.
6. Patients taking the following medications because of their potential interaction with quetiapine: Carbamazepine, clozapine, lithium, thioridazine.
7. History of CVA, or at significantly increased risk for CVA (e.g., atrial fibrillation, recent TIA etc.).
8. Symptomatic cardiovascular disease (i.e., angina, claudication, TIAs, syncope), uncontrolled hyper or hypotension, or a tic disorder.
9. Any medical contraindication to performing the procedures involved in the study including blood draws or lumbar puncture.
10. We will require a woman of child-bearing age to have a pregnancy test prior to starting the study medications and to use contraception during the course of the study.
11. Patients with a previous negative trial of a stimulant.
12. Patients with a history of severe psychosis.
13. Patients with a history of recent substance abuse.
14. Patients with QTc prolongation on a baseline EKG.
15. A score of 2 or less on the Communication Functional Ratings - Swallowing Domain.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
45 Years
Maximum Age:
95 Years
Study:
NCT00088751
Study Brief:
Protocol Section:
NCT00088751